Dianthus Therapeutics (NASDAQ:DNTH) Stock Rating Upgraded by Raymond James

Raymond James upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) to a moderate buy rating in a report released on Thursday morning,Zacks.com reports.

A number of other analysts have also recently weighed in on DNTH. Oppenheimer increased their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $23.81 on Thursday. The stock has a market capitalization of $704.78 million, a price-to-earnings ratio of -9.52 and a beta of 1.74. The firm’s fifty day simple moving average is $26.09 and its 200-day simple moving average is $26.57. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its holdings in Dianthus Therapeutics by 40.5% during the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock worth $25,936,000 after buying an additional 273,670 shares in the last quarter. State Street Corp lifted its position in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the period. Great Point Partners LLC boosted its stake in shares of Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after acquiring an additional 132,929 shares in the last quarter. Braidwell LP grew its holdings in shares of Dianthus Therapeutics by 34.6% in the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after acquiring an additional 126,836 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in Dianthus Therapeutics by 151.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after purchasing an additional 263,500 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.